ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
-0,50%
Bitcoin
66.839,47
2,45%
Brent Oil
83,76
0,67%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Agios Pharmaceuticals Inc (AGIO)

  7. Agios Pharmaceuticals Inc (AGIO) Notícias

AGIO

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AGIO
DataHoraFonteTítuloCódigoCompanhia
14/05/202411:00GlobeNewswire Inc.Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid CongressNASDAQ:AGIOAgios Pharmaceuticals Inc
06/05/202408:00GlobeNewswire Inc.Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
03/05/202408:00GlobeNewswire Inc.Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
02/05/202408:00GlobeNewswire Inc.Agios Reports Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:AGIOAgios Pharmaceuticals Inc
18/04/202408:00GlobeNewswire Inc.Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
09/04/202408:00GlobeNewswire Inc.Agios Publishes 2024 Environmental, Social and Governance (ESG) ReportNASDAQ:AGIOAgios Pharmaceuticals Inc
07/03/202420:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
05/03/202409:00GlobeNewswire Inc.Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
01/03/202418:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
22/02/202409:00GlobeNewswire Inc.Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
15/02/202412:33Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AGIOAgios Pharmaceuticals Inc
15/02/202409:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGIOAgios Pharmaceuticals Inc
15/02/202409:00GlobeNewswire Inc.Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:AGIOAgios Pharmaceuticals Inc
14/02/202416:21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AGIOAgios Pharmaceuticals Inc
02/02/202409:00GlobeNewswire Inc.Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
08/01/202409:00GlobeNewswire Inc.Agios Announces Key Anticipated 2024 Milestones Across Rare Disease PortfolioNASDAQ:AGIOAgios Pharmaceuticals Inc
03/01/202408:30GlobeNewswire Inc.Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-ThalassemiaNASDAQ:AGIOAgios Pharmaceuticals Inc
02/01/202409:00GlobeNewswire Inc.Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
09/12/202321:00GlobeNewswire Inc.Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and ExpositionNASDAQ:AGIOAgios Pharmaceuticals Inc
20/11/202309:00GlobeNewswire Inc.Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic SyndromesNASDAQ:AGIOAgios Pharmaceuticals Inc
02/11/202310:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGIOAgios Pharmaceuticals Inc
02/11/202310:05GlobeNewswire Inc.Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and ExpositionNASDAQ:AGIOAgios Pharmaceuticals Inc
02/11/202308:00GlobeNewswire Inc.Agios Reports Business Highlights and Third Quarter 2023 Financial ResultsNASDAQ:AGIOAgios Pharmaceuticals Inc
29/08/202308:00GlobeNewswire Inc.Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023NASDAQ:AGIOAgios Pharmaceuticals Inc
03/08/202307:35GlobeNewswire Inc.Agios Reports Business Highlights and Second Quarter 2023 Financial ResultsNASDAQ:AGIOAgios Pharmaceuticals Inc
03/08/202307:30GlobeNewswire Inc.Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia VeraNASDAQ:AGIOAgios Pharmaceuticals Inc
13/07/202308:00GlobeNewswire Inc.Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023NASDAQ:AGIOAgios Pharmaceuticals Inc
26/06/202307:30GlobeNewswire Inc.Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin ResponseNASDAQ:AGIOAgios Pharmaceuticals Inc
23/06/202317:39Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AGIOAgios Pharmaceuticals Inc
15/06/202317:18Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:AGIOAgios Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:AGIO

Seu Histórico Recente

COIN
DXYETH
DXY.FINANCE
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados